Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07672717 · ClinicalTrials.gov registry record · Phase 1
Cabotegravir-Hormone PK/PD Interactions for HIV Prevention
A Phase 1 study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07672717: Recruiting Phase 1 study, sponsored by Johns Hopkins University.
NCT07672717 is a Phase 1 study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07672717, a Phase 1 study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical problems when taking CAB-LA.
Primary Outcome
Plasma CAB concentration in ng/mL, stratified by sex and therapeutic hormone status
Interventions
- DRUG Cabotegravir Injectable Suspension (CAB LA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
What NCT07672717 shows while recruiting
NCT07672717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Cabotegravir Injectable Suspension (CAB LA) is the first listed.
NCT07672717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07672717 about?
NCT07672717 is a clinical study titled "Cabotegravir-Hormone PK/PD Interactions for HIV Prevention". This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical prob...
What is the current status of trial NCT07672717?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-07. Estimated completion is 2031-12.
What interventions are being tested in trial NCT07672717?
The interventions under investigation include: Cabotegravir Injectable Suspension (CAB LA) (DRUG).
Who is sponsoring clinical trial NCT07672717?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07672717's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia